MR Intensity Normalization Methods Impact Sequence Specific Radiomics Prognostic Model Performance in Primary and Recurrent High-Grade Glioma.

high-grade glioma image preprocessing intensity harmonization intensity standardization multiparametric MRI radiomics signatures

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
02 Feb 2023
Historique:
received: 07 01 2023
revised: 30 01 2023
accepted: 31 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

This study investigates the impact of different intensity normalization (IN) methods on the overall survival (OS) radiomics models' performance of MR sequences in primary (pHGG) and recurrent high-grade glioma (rHGG). MR scans acquired before radiotherapy were retrieved from two independent cohorts (rHGG C1: 197, pHGG C2: 141) from multiple scanners (15, 14). The sequences are T1 weighted (w), contrast-enhanced T1w (T1wce), T2w, and T2w-FLAIR. Sequence-specific significant features (SF) associated with OS, extracted from the tumour volume, were derived after applying 15 different IN methods. Survival analyses were conducted using Cox proportional hazard (CPH) and Poisson regression (POI) models. A ranking score was assigned based on the 10-fold cross-validated (CV) concordance index (C-I), mean square error (MSE), and the Akaike information criterion (AICs), to evaluate the methods' performance. Scatter plots of the 10-CV C-I and MSE against the AIC showed an impact on the survival predictions between the IN methods and MR sequences (C1/C2 C-I range: 0.62-0.71/0.61-0.72, MSE range: 0.20-0.42/0.13-0.22). White stripe showed stable results for T1wce (C1/C2 C-I: 0.71/0.65, MSE: 0.21/0.14). Combat (0.68/0.62, 0.22/0.15) and histogram matching (HM, 0.67/0.64, 0.22/0.15) showed consistent prediction results for T2w models. They were also the top-performing methods for T1w in C2 (Combat: 0.67, 0.13; HM: 0.67, 0.13); however, only HM achieved high predictions in C1 (0.66, 0.22). After eliminating IN impacted SF using Spearman's rank-order correlation coefficient, a mean decrease in the C-I and MSE of 0.05 and 0.03 was observed in all four sequences. The IN method impacted the predictive power of survival models; thus, performance is sequence-dependent.

Identifiants

pubmed: 36765922
pii: cancers15030965
doi: 10.3390/cancers15030965
pmc: PMC9913466
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : H2020 MSCA-ITN PREDICT
ID : 766276

Références

Radiology. 2016 Dec;281(3):907-918
pubmed: 27636026
NPJ Precis Oncol. 2021 Jul 26;5(1):72
pubmed: 34312469
Med Image Anal. 2011 Apr;15(2):267-82
pubmed: 21233004
Magn Reson Imaging. 2004 Jan;22(1):81-91
pubmed: 14972397
IEEE Trans Med Imaging. 2001 Jan;20(1):45-57
pubmed: 11293691
Magn Reson Med. 1999 Dec;42(6):1072-81
pubmed: 10571928
AJNR Am J Neuroradiol. 2020 Jan;41(1):40-48
pubmed: 31857325
Eur Radiol. 2021 Apr;31(4):2084-2093
pubmed: 33006658
Oncogene. 2016 Nov 10;35(45):5819-5825
pubmed: 27041580
Radiol Med. 2021 Oct;126(10):1296-1311
pubmed: 34213702
Radiology. 2018 Dec;289(3):797-806
pubmed: 30277442
PLoS One. 2019 Mar 7;14(3):e0213459
pubmed: 30845221
Eur Radiol. 2021 Apr;31(4):2272-2280
pubmed: 32975661
Front Neurosci. 2021 May 13;15:683452
pubmed: 34054424
Sci Rep. 2017 Oct 30;7(1):14331
pubmed: 29085044
Neuroimage. 2020 Feb 1;206:116324
pubmed: 31704293
Eur Radiol. 2017 Oct;27(10):4188-4197
pubmed: 27778090
Neuro Oncol. 2015 Sep;17(9):1188-98
pubmed: 26250565
Biostatistics. 2007 Jan;8(1):118-27
pubmed: 16632515
Neuroimage. 2020 Oct 15;220:117129
pubmed: 32640273
Neuroimage. 2008 Feb 1;39(3):1180-5
pubmed: 18032068
Eur Radiol. 2022 Oct;32(10):7014-7025
pubmed: 35486171
Eur J Radiol. 2019 Nov;120:108609
pubmed: 31606714
J Magn Reson Imaging. 2018 Dec;48(6):1518-1528
pubmed: 29573085
IEEE J Biomed Health Inform. 2019 Mar;23(2):795-804
pubmed: 29993848
Eur Radiol. 2021 Apr;31(4):1785-1794
pubmed: 33409797
Eur Radiol. 2019 Oct;29(10):5528-5538
pubmed: 30847586
Proc SPIE Int Soc Opt Eng. 2019 Mar;10949:
pubmed: 31551645
Neuro Oncol. 2014 May;16(5):696-706
pubmed: 24335699
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Radiology. 2018 Oct;289(1):128-137
pubmed: 30063191
Neuroimage Clin. 2018;20:1070-1077
pubmed: 30366279
BMC Neurol. 2017 Sep 5;17(1):172
pubmed: 28874119
J Comput Assist Tomogr. 2022 May-Jun 01;46(3):470-479
pubmed: 35405713
Magn Reson Imaging. 2020 Dec;74:161-170
pubmed: 32980505
BMC Cancer. 2010 Oct 06;10:533
pubmed: 20925951
Sci Rep. 2020 Jul 23;10(1):12340
pubmed: 32704007
Front Comput Neurosci. 2020 Aug 04;14:61
pubmed: 32848682
Hum Brain Mapp. 2019 Dec 1;40(17):4952-4964
pubmed: 31403237
Med Phys. 2019 Nov;46(11):5116-5123
pubmed: 31539450
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Sci Rep. 2017 Sep 4;7(1):10353
pubmed: 28871110
Comput Biol Med. 2016 Nov 1;78:49-57
pubmed: 27658261
Biometrics. 1983 Sep;39(3):665-74
pubmed: 6652201
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Med Biol Eng Comput. 2018 Dec;56(12):2287-2300
pubmed: 29915951
Eur Radiol. 2020 Jul;30(7):3834-3842
pubmed: 32162004
Neuroimage. 2006 May 1;30(4):1196-202
pubmed: 16380273
Methods. 2021 Apr;188:20-29
pubmed: 32504782
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
BMC Cancer. 2010 Sep 06;10:478
pubmed: 20819220
J Med Imaging (Bellingham). 2020 May;7(3):031505
pubmed: 32566694
Radiology. 2016 Sep;280(3):880-9
pubmed: 27326665
Neuroimage Clin. 2014 Aug 15;6:9-19
pubmed: 25379412
Front Neurosci. 2019 Sep 20;13:966
pubmed: 31619949
Mod Pathol. 2013 Jul;26(7):922-9
pubmed: 23429602
Oncotarget. 2019 Jan 18;10(6):660-672
pubmed: 30774763
Brain. 2022 Apr 29;145(3):1151-1161
pubmed: 35136934
Transl Oncol. 2021 Jun;14(6):101065
pubmed: 33761371
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Phys Med Biol. 2019 Aug 21;64(16):165011
pubmed: 31272093
Sci Rep. 2020 Jun 24;10(1):10248
pubmed: 32581221
Cancers (Basel). 2021 Jun 15;13(12):
pubmed: 34203896

Auteurs

Patrick Salome (P)

Clinical Cooperation Unit (CCU) Radiation Oncology, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.
Heidelberg Medical Faculty, Heidelberg University, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK) Core Centre Heidelberg, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.

Francesco Sforazzini (F)

Clinical Cooperation Unit (CCU) Radiation Oncology, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.
Heidelberg Medical Faculty, Heidelberg University, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK) Core Centre Heidelberg, 69120 Heidelberg, Germany.

Gianluca Grugnara (G)

Department of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Andreas Kudak (A)

Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany.
CCU Radiation Therapy, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.

Matthias Dostal (M)

Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany.
CCU Radiation Therapy, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.

Christel Herold-Mende (C)

Brain Tumour Group, European Organization for Research and Treatment of Cancer, 1200 Brussels, Belgium.
Division of Neurosurgical Research, Department of Neurosurgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Sabine Heiland (S)

Department of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Jürgen Debus (J)

German Cancer Consortium (DKTK) Core Centre Heidelberg, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany.

Amir Abdollahi (A)

Clinical Cooperation Unit (CCU) Radiation Oncology, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK) Core Centre Heidelberg, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany.

Maximilian Knoll (M)

Clinical Cooperation Unit (CCU) Radiation Oncology, German Cancer Research Centre, INF 280, 69120 Heidelberg, Germany.
German Cancer Consortium (DKTK) Core Centre Heidelberg, 69120 Heidelberg, Germany.
Heidelberg Ion-Beam Therapy Centre (HIT), INF 450, 69120 Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, INF 400, 69120 Heidelberg, Germany.

Classifications MeSH